Mortby, Moyra E.Adler , LawrenceAgüera-Ortiz , LuisBateman, Daniel R.Brodaty , HenryCantillon , MarcGeda , Yonas E.Ismail, ZahinoorLanctôt, Krista L.Marshall, Gad A.Padala, Prasad R.Politis, AntoniosRosenberg, Paul B.Siarkos, KostasSultzer, David L.Theleritis, ChristosISTAART NPS PIA2024-06-212024-06-212022-02Mortby, M. E., Adler, L., Agüera-Ortiz, L., Bateman, D. R., Brodaty, H., Cantillon, M., Geda, Y. E., Ismail, Z., Lanctôt, K. L., Marshall, G. A., Padala, P. R., Politis, A., Rosenberg, P. B., Siarkos, K., Sultzer, D. L., & Theleritis, C. (2022). Apathy as a Treatment Target in Alzheimer’s Disease: Implications for Clinical Trials. The American Journal of Geriatric Psychiatry, 30(2), 119–147. https://doi.org/10.1016/j.jagp.2021.06.016https://hdl.handle.net/1805/41746Apathy is one of the most prevalent, stable and persistent neuropsychiatric symptom across the neurocognitive disorders spectrum. Recent advances in understanding of phenomenology, neurobiology and intervention trials highlight apathy as an important target for clinical intervention. We conducted a comprehensive review and critical evaluation of recent advances to determine the evidence-based suggestions for future trial designs. This review focused on 4 key areas: 1) pre-dementia states; 2) assessment; 3) mechanisms/biomarkers and 4) treatment/intervention efficacy. Considerable progress has been made in understanding apathy as a treatment target and appreciating pharmacological and non-pharmacological apathy treatment interventions. Areas requiring greater investigation include: diagnostic procedures, symptom measurement, understanding the biological mechanisms/biomarkers of apathy, and a well-formed approach to the development of treatment strategies. A better understanding of the subdomains and biological mechanisms of apathy will advance apathy as a treatment target for clinical trials.en-USAttribution-NonCommercial-NoDerivatives 4.0 Internationalapathytreatment targetneurocognitive disordersmechanisms and biomarkersassessmenttreatment and interventionpre-dementia statesfuture directionsISTAART neuropsychiatric syndromes professional interest areaArticle